我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Prognostic Factors in Pancreatic Cancer: The Role of Perineural, Vascular and Lymphatic Invasion and of Ca19-9

Berardi R, Mandolesi A, Pellei C, Maccaroni E, Onofri A, Lucarelli A, Biagetti S, Alfonsi S, Caramanti M, Savini A, Bearzi I and Cascinu S

Objective: The aim of our analysis was to investigate the impact of perineural, vascular and lymphatic invasion and of CA19-9 on survival in patients with locally advanced and metastatic pancreatic cancer, with the objective to serve as a tool for a more accurate and rational treatment selection. Methods: We analyzed 181 consecutive patients with locally advanced unresectable pancreatic cancer and metastatic pancreatic cancer who received chemotherapy at our Institution between 2000 and 2010. Results: At univariate analysis CA19-9 represented a prognostic factor (median overall survival if CA19-9 ≤ 37 U/ml vs. >37 U/ml was 18.49 vs. 9.21 months, respectively, p=0,0004), while surprisingly the presence of vascular, lymphatic and perineural invasion was found to be a favorable prognostic factor (median overall survival in patients with invasion vs. without invasion was 27.5 vs. 9.6 months, respectively, p=0.0002).At multivariate analysis the presence of invasion was found to be an independent favorable prognostic factor, while the high level of CA19-9 resulted an independent unfavorable prognostic factor. Conclusion: High values of CA19-9 at the beginning of the first-line chemotherapy represent an independent prognostic factor, therefore it should be taken into consideration to select the treatment. Surprisingly the presence of invasion appeared as an independent favorable prognostic factor in locally advanced and metastatic pancreatic cancer and this result may impact therapy decisions and stratification of future clinical trials.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。